Ross Jeffrey S, Sheehan Christine E, Fisher Hugh A G, Kauffman Ronald A, Dolen Eric M, Kallakury Bhaskar V S
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA.
Expert Rev Mol Diagn. 2002 Mar;2(2):129-42. doi: 10.1586/14737159.2.2.129.
In this review, a series of relatively well-documented ancillary biomarkers and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and classified as Category I by the College of American Pathologists Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (Category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or clinical trials (Category III).
在本综述中，我们评估了一系列记录相对完备的辅助生物标志物和新兴分子检测方法，以了解它们预测前列腺癌预后的相对能力。将已广泛应用并被美国病理学家学会实体瘤预后因素共识会议列为I类的预后因素，与已开始在临床实践中使用的较新检测方法（II类）以及尚未在已发表文献或临床试验中得到广泛验证的新兴分子检测方法（III类）进行比较。
